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Introduction
Paroxysmal nocturnal hemoglobinuria (PNH) is a rare
disease. Its prevalence is estimated to be approxi-
mately 1–10 cases per million population [1]. Three
common manifestations of PNH are hemolytic anemia,
venous thrombosis and deficient hematopoiesis [1].
Maternal complications related to PNH are seen in
three-quarters of patients. The most frequent causes of
PNH-related fetomaternal morbidity and mortality are
hemolysis and thrombosis [1,2]. PNH should be dis-
tinguished from preeclampsia or HELLP (hemolysis,
elevated liver enzymes and low platelets) syndrome dur-
ing pregnancy. However, there are exceptional cases
when PNH is superimposed with preeclampsia. Here,
we present a case of PNH complicated with severe pre-
eclampsia in the third trimester.
Case Report
A 30-year-old, gravida 1, para 0, woman had PNH,
diagnosed at the age of 17. Initially, she was treated
with prednisolone (5 mg twice daily) and danazol
(200 mg three times daily). However, severe pancy-
topenia developed subsequently. Bone marrow trans-
plantation was suggested, but was not undertaken as
no compatible bone marrow donor came forward. She
was treated with the same regimen of prednisolone
and danazol, with the addition of folic acid and iron
supplements. Her PNH was stable under medication.
Laboratory test results before pregnancy were: platelets
80,000/cmm, lactate dehydrogenase (LDH) 1,300 U/L,
asparate aminotransferase (AST) 60 U/L and total
bilirubin 1.6 mg/dL.
PAROXYSMAL NOCTURNAL HEMOGLOBINURIA
SUPERIMPOSED WITH PREECLAMPSIA
Mann-Ling Chen, Chen-Hsiang Yu*, Fong-Ming Chang, Pao-Lin Kuo
Department of Obstetrics and Gynecology, National Cheng Kung University Medical Center, Tainan, Taiwan.
SUMMARY
Objective: Paroxysmal nocturnal hemoglobinuria (PNH) is a rare hematologic disorder characterized by 
complement-mediated intravascular hemolysis. As maternal complication of PNH is already severe, it becomes
much more complex when preeclampsia is superimposed. We present a case of PNH superimposed with severe
preeclampsia in the third trimester.
Case Report: A 30-year-old, gravida 1, para 0, woman had PNH, diagnosed at the age of 17. Her PNH was stable
under medication. In 2004, she conceived and had prenatal care at our hospital. At 35 weeks of gestation,
preeclampsia with elevated blood pressure and proteinuria were superimposed and managed with close surveil-
lance. A live male baby was delivered vaginally at 38 weeks of gestation. During parturition, her blood pressure
increased to 180/100 mmHg. Thrombocytopenia, hyponatremia, hyperkalemia, hypoalbuminemia, elevated liver
enzymes and lactate dehydrogenase were also noted. Preeclampsia continued to postpartum and eventually
disappeared.
Conclusion: The most frequent causes of PNH-related fetomaternal morbidity and mortality are hemolysis and
thrombosis. The situation becomes even more complicated when PNH is superimposed with preeclampsia.
Appropriate clinical surveillance, awareness of the potential risks of hemolysis and thrombosis, as well as evalua-
tion of fetal wellbeing are essential. [Taiwanese J Obstet Gynecol 2006;45(3):276–278]
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In 2004, she conceived and had regular prenatal
care at our hospital. Her pregnancy was uneventful
until 35 weeks of gestation, when elevated blood pres-
sure (>140/90 mmHg) and proteinuria (+++) were
noted. PNH superimposed with preeclampsia was sus-
pected. The antihypertensive agent, hydralazine, 10 mg
three times a day was prescribed to control blood
pressure. At 38 weeks of gestation, she delivered a live
male baby, with birth weight 2,510 g, birth length
47 cm and 1- and 5-minute Apgar scores of 9 and 10,
respectively.
However, her blood pressure increased to 180/
100 mmHg during parturition. Laboratory tests showed
thrombocytopenia (87,000/cmm), hyponatremia (128
mmol/L), hyperkalemia (5.2 mmol/L), hypoalbumi-
nemia (2.2 g/dL), elevated liver enzymes (AST 123 U/L,
total bilirubin 2.2 mg/dL) and LDH 1,695 U/L. General
weakness and hyperreflex developed immediately after
delivery. PNH superimposed with HELLP was consid-
ered. Nevertheless, no tea-colored urine, headache,
abdominal pain and blurred vision were observed.
Magnesium sulfate was given for 24 hours to prevent
convulsion, and her blood pressure was controlled with
medication. The abnormal laboratory findings soon
returned to baseline levels 1 day after delivery. Elevated
blood pressure also diminished after discharge. To date,
1 year after delivery, her PNH remains inactive.
Discussion
PNH is a rare hematologic disorder characterized by
complement-mediated intravascular hemolysis, result-
ing in a nonimmune hemolytic anemia and thrombo-
cytopenia, as well as a hypercoagulable state with
venous thrombosis [1,2]. It results from a clonal
defect in a single hematopoietic stem cell. The progeny
of this defective stem cell, erythrocytes, leukocytes and
platelets, are all dysfunctional by virtue of their partial
or complete lack of surface proteins linked to the
membrane by a glycosylphosphotidylinositol (GPI)
anchor [3]. Recently, the advent of flow cytometry
assays of GPI-anchored proteins allowed screening for
PNH. Cytoflowmetry is more sensitive than the tradi-
tional Ham’s test and is not influenced by transfusion
[3]. In our case, Ham’s test was positive 13 years ago,
which supports the diagnosis of PNH.
For clinical manifestations of PNH, hemolysis may
be initiated by transfusions, infections or surgery.
Clinical hemoglobinuria (tea-colored urine) is inter-
mittent in most patients and never occurs in some, but
hemosiderinuria is usually present. LDH is present in
erythrocytes in high concentrations and when elevated
may be a sign of hemolysis. The hypercoagulable ten-
dency of PNH relates to the fact that platelets of
affected patients are able to bind greater amounts 
of complement (C3) than normal platelets. Activation
of the complement pathway then triggers the platelet
release and aggregation mechanism, potentially result-
ing in thrombosis. Thrombosis may affect hepatic,
portal, renal, cerebral, mesenteric or dermal sites, with
the last sometimes resulting in unusual necrotic skin
lesions [1]. In our case, tea-colored urine and elevated
LDH and liver enzymes appeared 5 years before preg-
nancy and subsided after conception.
In pregnancy, hepatic vein thrombosis (Budd–Chiari
syndrome) is the most common thrombotic complica-
tion, with a peak incidence in the postpartum period.
Maternal complications related to PNH are seen in
three-quarters of patients and maternal mortality is
around 10% and fetal loss around 40%. The most fre-
quent causes of fetomaternal morbidity and mortality
include hemolysis and thrombosis [2,4]. During preg-
nancy, hemolytic anemia and thrombocytopenia may
be common manifestations of other diseases. PNH
should be distinguished from preeclampsia, dissemi-
nated intravascular coagulation, thrombotic thrombo-
cytopenic purpura, hemolytic uremic syndrome and
acute fatty liver of pregnancy. Our patient had PNH
for more than 13 years, which was controlled well with
iron and folic acid supplements. As no acute hemolysis
occurred during pregnancy, her PNH was stable without
the treatment of prednisolone and danazol.
The differential diagnosis between PNH and pre-
eclampsia is important. Unlike the pathogenesis of
PNH, which was activation of the complement path-
way, the vasospasm, part of the pathophysiology of
preeclampsia, is likely to result in endothelial injury.
Vasospasm could be the cause of the microangiopathic
hemolysis and might induce thrombocytopenia, ane-
mia and fragmentation of red blood cells (RBCs). In
addition, there was development of hypertension and
proteinuria, which was absent in PNH patient (Table).
Preeclampsia may be associated with other signs and
symptoms such as edema, visual disturbance, headache
and upper abdominal pain. In severe preeclampsia with
HELLP syndrome, there was elevated liver enzymes due
to periportal hemorrhagic necrosis in the periphery of
the liver lobule. Bleeding from those lesions or from
the liver capsule can lead to subcapsular hematoma
[5]. Thrombocytopenia and hemolysis may also occur
as part of the HELLP syndrome [5]. From the Table,
our patient had hypertension (> 140/90 mmHg) and
proteinuria in the third trimester, which are essential
parts of preeclampsia and HELLP as well, and should
not appear in PNH. Therefore, our case was most likely
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a case of PNH superimposed with preeclampsia and
HELLP syndrome.
Treatment for PNH includes blood transfusion, not
only to increase hemoglobin concentration, but also to
suppress marrow production of complement-sensitive
erythrocytes during episodes of sustained hemo-
globinuria. The use of washed erythrocytes (RBCs) to
maintain a hemoglobin concentration of at least
10 g/L has been the most common practice. Washed
RBCs has been advocated in order to remove the
potentially damaging source of complement on trans-
fused red cells. In addition, folic acid and iron replace-
ment are also advocated. However, intravenous iron
infusions in particular may cause an exacerbation of
hemolysis due to the formation of a large number 
of young erythrocytes, which are more sensitive to 
the effects of complement. This hemolytic effect can
be reduced by oral iron therapy in conjunction with
the judicious use of blood transfusions. Persistent or
severe hemolysis can be treated with oral prednisolone
(at a dose of 0.5–1.0 mg/kg/day), which reduces the
rate of complement activation and thus diminishes the
rate of hemolysis. Besides, androgen therapy (dana-
zol) may increase hemoglobin levels but is contraindi-
cated in pregnancy [1]. Our patient had taken folic
acid, iron, prednisolone and androgen therapy before
pregnancy. After pregnancy, only folic acid and iron
replacement were prescribed.
The best management for preeclampsia and HELLP
syndrome is delivery. Blood pressure should be con-
trolled carefully to prevent complications, such as mater-
nal cerebrovascular accidents and placental abruptios.
Antihypertensive therapy is usually recommended.
Hydralazine is the most widely accepted drug for treat-
ing hypertension in severe preeclampsia. Prevention of
convulsions with magnesium sulfate should also be
considered. In our case, hydralazine was prescribed 
for controlling blood pressure. At parturition, sudden
elevated blood pressure (180/100 mmHg) with hyper-
reflex emerged. The laboratory data showed throm-
bocytopenia, elevated liver enzymes and LDH that
resembled the HELLP syndrome. We had given magne-
sium sulfate to prevent convulsion for 24 hours and all
the symptoms and signs of HELLP syndrome subsided
1 day after delivery.
In conclusion, the primary challenge in the man-
agement of PNH and preeclampsia during pregnancy
is differential diagnosis. Nevertheless, a patient with
PNH may also have superimposed preeclampsia and
HELLP syndrome during pregnancy. Since PNH is a
rare disorder with remarkably high fetomaternal mor-
bidity and mortality, it is much more complicated when
preeclampsia and HELLP syndrome are superimposed.
PNH superimposed with HELLP syndrome should be
closely monitored. Management should combine treat-
ments for PNH and preeclampsia with HELLP syn-
drome. Appropriate clinical surveillance, awareness of
the potential risk of hemolysis and thrombosis as well
as close observation of maternal–fetal wellbeing are
highly recommended. We suggest that cases with PNH
and HELLP should be identified as a high-risk preg-
nancy as soon as possible, and transferred to a tertiary
medical center for comprehensive management.
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Table. Differential diagnosis among paroxysmal noctur-
nal hemoglobinuria (PNH), preeclampsia with HELLP and
PNH superimposed with HELLP*
Characteristics PNH
Preeclampsia This 
with HELLP case
Pathogenesis
Activation of + − +
complement pathway
Vasospasm − + +
Deficient hematopoiesis
Granulocytopenia + − −
Thrombocytopenia + ++ +
Intravascular hemolysis + + +
Hemoglobinuria + − −
Hemosiderinuria + − −
Elevated LDH + + +
Venous thrombosis + − −
Elevated blood pressure − +++ +++
Proteinuria − +++ +++
Generalized edema − +++ −
Liver enzymes elevation − ++ ++
*From this Table, PNH superimposed with preeclampsia and HELLP syn-
drome is the most appropriate diagnosis for this case. HELLP = hemolysis, ele-
vated liver enzymes and low platelets; LDH = lactate dehydrogenase.
